Artificial Intelligence Markets in Medical Diagnostics, 2019: AI is Revolutionizing the Healthcare Industry - The Most Targeted Medical Applications, and Which Companies are Going for Them?

News provided by

Aug 14, 2019, 10:15 ET

DUBLIN, Aug. 14, 2019 /PRNewswire/ -- The "Artificial Intelligence in Medical Diagnostics" report has been added to ResearchAndMarkets.com's offering.

With the development of deep learning and neural networks, artificial intelligence (AI) has gained learning capabilities. The result is that some new AIs can now recognize patterns better than human eyes. It paves the way for the emergence of a new generation of medical diagnostic devices capable of surpassing the detection skills of the best medical practitioners. Because artificial intelligence can be replicated, the expertise of these systems can become accessible to a large number of patients.

Moreover, AI has numerous and diverse applications in medical diagnostics, such as image analysis for tumor detection, video detection for gait disorders and fall prediction, biochemical tests such as for diabetes or speech analysis of emotional state and psychiatric disorders. Therefore, AI will considerably disrupt the traditional model of medical diagnosis.

More than US$1.1 billion has been invested since 2016 by companies working on the development of artificial intelligence for medical imaging. Companies such as Heartflow received US$340 million investment in the past 5 years. The main expected players in this market are the medical diagnostic systems manufacturers like. General Electric, Philips and Siemens, but also artificial intelligence-guru companies like IBM or Microsoft.

Besides these big companies, the number of Intellectual Property (IP) newcomers is important and growing. Unlike the development of new medical devices, artificial intelligence software development costs are moderate. As a result, the number of IP newcomers developing innovative software is likely to continue to rise sharply in the coming years.

Thereby, with the emergence of many new companies like Aidence, Bay Labs and doc.ai, and given the many advantages and new applications of AI for medical diagnostics, it is crucial to understand the intellectual property (IP) position and strategy of these different players. Such knowledge can help detect business risks and opportunities, anticipate emerging applications and enable strategic decisions to strengthen one's market position.

The analysis of the time evolution of patent publications shows that the development of medical diagnostic systems with built-in computer-assisted detection features is not new. The first patents related to this topic were published in the 1980s. In the 1990s Japanese medical imaging system manufacturers like Toshiba, Fujifilm, Topcon, Fujitsu, and Hitachi started to invest investigate this topic soon followed by European companies like Siemens and Philips and then by American companies like IBM, Medtronic and General Electric.

The number of patent families published each year increased progressively until 2015. Since then it has rapidly increased, and now we see the publication of more than 1,100 new patent families in 2018. This shows that AI in medical diagnostics is a very hot topic that is mobilizing great R&D efforts from different players.

The main patent assignee in the field of this study is Siemens, with more than 500 patent families. It is followed by Philips and General Electric, with more than 150 patent families each. Most main patent assignees have developed an international IP strategy. Europe-based corporations are showing the widest geographical protection for their inventions. American players mainly protect their inventions in the US and to a lesser extent in Europe and in Asian countries.

Identifying the companies that have recently emerged in the IP landscape

Among the players that have filed patents about AI in medical diagnostics, over 90 newcomers were identified. Many of these companies are startup firms currently developing their first products. These products consist of software solutions such as software for ultrasound imaging analysis, image resolution improvement or real-time brain monitoring, or medical devices capable of live analysis of biological parameters such as blood glucose monitoring apparatus, sleep monitoring sensors and ECG. Numerous IP newcomers are based in the US while some are based in Israel, in Europe or in Asia. It is possible that one of these innovative companies could become one of the next healthcare unicorns' that big corporations will be tempted to acquire.

Key Topics Covered:

1. Introduction

AI in medical diagnostics
Scope of the report
Key features of the report
Objectives of the report

2. Methodology

Patent search, selection and analysis
Search strategy
Key patent identification
Terminologies for patent analysis

3. Main Assignees Mentioned

4. Executive Summary

Patent Landscape Overview

Global overview
Time evolution of patent publications
Countries of patent filings
Time evolution by country of filing
Main patent assignees
Mapping of main current IP holders
Patenting activity of IP leading companies
Time evolution for main patent assignees

IP position of the main patent assignees

Strength index of patent portfolios
IP specialization degree
IP blocking potential of patent applicants
IP leadership of patent applicants
Summary of applicant's patent portfolios
Patent assignees' main collaboration network
Recent collaborations

5. Key Patent Families

Potential future plaintiffs
Description of the Key Patent Families

6. Main Patent Litigations

Hemopet v. Nestl Purina Petcare and Hill's Pet Nutrition
Bessette Intellectual Property et al v. CVS Health, Walgreen and Wal Mart Stores
Health Discovery v. Equbits and Ciphergen Biosystems
Kaniadakis v. Salesforce.com et al
Dexcom v. Agamatrix
Avery et al v. Barsky
Healthways and Robert Bosch v. Alere
LD Technology LLC v. Impeto Medical SAS et al
Fitbit, Inc. v. AliphCom et al
Siemens Med. Sol. USA => Cerner Health Services v. Humedica
Alt v. Medtronic
Medical Priority Consultants et al v. VitalClick
Philips North America v. Fitbit and Garmin International
Potential future plaintiffs

7. Presentation of the IP Newcomers

Identification methodology
Introduction to the IP newcomers
Identification of the IP newcomers

8. Analysis By Segments

Focus on the medical examination modalities

Biochemical tests
Blood pressure
Cardiopulmonary sounds
Computed tomography (CT) scanners
Elastography
Electrocardiography
Electroencephalography
Electromyography
Facial analysis
Magnetic Resonance Imaging
Minimally invasive imaging
Movement analysis
Optical Coherence Tomography (OCT) imaging
Photoacoustic imaging
Positron-Emitting Tomography (PET) scanners
Speech analysis
Ultrasound imaging
X-rays

Focus on the clinical specialties

Allergies
Anesthesia monitoring
Arthropathology & Osteopathology
Brain injuries & Neurodegenerative diseases
Cardiology & Angiology
Diabetes
Gait disorder & Fall prediction
Hepatology
Infectiology
Irritable bowel syndrome/Inflammatory Bowel Disease
Ophthalmology
Pneumopathology
Pregnancy-related & Fetal conditions
Psychology & Psychiatry
Sleep disorders
Stomatology
Oncology
Breast cancer
Colorectal cancer
Liver cancer
Lung cancer
Prostate cancer
Skin cancer

9. Conclusion

Companies Mentioned

Abbott
Ajinomoto
Aliph
Alphabet
Bausch Health
Berg Pharma
Biomerieux
Boston Scientific
Bracco
Canon
Carestream Health
Caris Life Sciences
Carl Zeiss
Cognoa
Dexcom
Facense
Fujifilm
Fujitsu
General Electric
Heartflow
Hitachi
Hologic
IBM
Imaging Therapeutics
Johnson & Johnson
Konica
Medtronic
Myskin
Nestl
Olympus
Philips
Resmed
Roche
Samsung
Sensys Medical
Siemens
Topcon
Veracyte
Vermillion
Zoll Medical

For more information about this report visit https://www.researchandmarkets.com/r/dg0zvu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets